ReproHepato Human iPS Cell-derived Hepatocytes

Catalog RCDH001N
Size 8.25 million cells
Price
$850.00
$850.00
Availability In stock
Catalog
RCDH001N

Product Overview

ReproHepato™: The world’s first commercial human iPS cell-derived hepatocytes

ReproHepato cells are a high-quality, available source of human hepatocytes for drug metabolism or other physiological studies.  ReproHepato cells are differentiated from iPS cells, providing a nearly inexhaustable source of hepatocytes with consistent genetics and physiology, unlike primary human hepatocytes that vary considerably from lot-to-lot. 

  • Express robust CYP450 enzyme activity including CYP3A4, CYP1A2, CYP2C9, and CYP2C19
  • Demonstrate inducible expression and metabolic CYP450 activity 
  • Display high lot-to-lot consistency
  • Possess a long life-span in culture retaining robust metabolic activity

After six days growth of ReproHepato cells in ReproHepato Culture Medium, the cells have reached maximum maturity and are ready for use in assays.  It is recommended to use ReproHepato Assay Medium for CYP enzyme analysis.  These media are specially optimized for culture and assay of ReproHepato human iPSC-derived hepatocytes.

RCDH001N: ReproHepato Human iPSC-derived Hepatocytes:

  • Derived from RNA-reprogrammed human iPSC (healthy 32-year-old, male)
  • Frozen single cell suspension of nearly mature human hepatocytes
  • 8.25 x 106 cells (enough to seed an entire 96-well plate)
  • Stable "indefinitely" when stored in liquid nitrogen


Product Specifications

Product Name
ReproHepato Human iPS Cell-derived Hepatocytes
Catalog Number
RCDH001N
Size
8.25 million cells
Storage and Stability
store in liquid nitrogen
Related Products
CYP Assay Service
Hepatotoxicity assay service


Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC Asia's 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society(Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan(Okayama), March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan.
  • Inamura, Mitsuru and Yokoyama, Chikafumi. "Human iPS cell-derived hepatocytes for drug screening." Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.

Publications

  • Inamura, Mitsuru and Yokoyama, Chikafumi. “Human iPS cell-derived hepatocytes for drug screening.” Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. “Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.” Toxicology letters 219.1 (2013): 49-58.

Product Specifications

Product Name
ReproHepato Human iPS Cell-derived Hepatocytes
Catalog Number
RCDH001N
Size
8.25 million cells
Storage and Stability
store in liquid nitrogen
Related Products
CYP Assay Service
Hepatotoxicity assay service

Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC Asia's 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society(Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan(Okayama), March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan.
  • Inamura, Mitsuru and Yokoyama, Chikafumi. "Human iPS cell-derived hepatocytes for drug screening." Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.

Publications

  • Inamura, Mitsuru and Yokoyama, Chikafumi. “Human iPS cell-derived hepatocytes for drug screening.” Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. “Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.” Toxicology letters 219.1 (2013): 49-58.